Investors recently learned about undisclosed data from one of Amgen's clinical trials. The new information didn't look favorable at first glance. During clinical trials, especially those in phase 1 safety testing, investigators are obligated to capture a ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 people who were overweight or obese, the company said on Tuesday.

Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's Zepbound.

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight management candidate. According to the giant drugmaker, treatment with an anti-obesity candidate called MariTide helped patients reduce their weight by up to 20% after 52 weeks.

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other experimental treatments.

An Amgen obesity drug helped participants lose a substantial amount of weight, but questions about how competitive it could be remain

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 percent of their weight in a year. The drug, MariTide, is given by injection once a month, compared with once a week for other obesity drugs like Wegovy and Zepbound that are already on the market.

The pharmaceutical company's MariTide treatment performed well in a Phase 2 study but not as well as Wall Street expected.

Amgen's experimental weight loss injection, MariTide, showed up to 20% weight loss in patients without diabetes and 17% in those with diabetes after a year in a phase 2 trial. Despite higher discontinuation rates compared to other drugs,